Duavee, Conbriza(bazedoxifene)
Conbriza, Duavee, Duavive (bazedoxifene) is a small molecule pharmaceutical. Bazedoxifene was first approved as Conbriza on 2009-04-17. It is used to treat menopause in the USA. It has been approved in Europe to treat postmenopausal osteoporosis and postmenopause. The pharmaceutical is active against estrogen receptor beta and estrogen receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Combinations
Duavee
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| menopause | EFO_0003922 | D008593 | N95 |
Agency Specific
FDA
EMA
No data
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03C: Estrogens, sex hormones and modulators of the genital system
— G03CC: Estrogens, combinations with other drugs
— G03CC07: Conjugated estrogens and bazedoxifene
— G03X: Other sex hormones and modulators of the genital system in atc
— G03XC: Selective estrogen receptor modulators
— G03XC02: Bazedoxifene
HCPCS
No data
Clinical
Clinical Trials
55 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | 3 | 2 | 6 | 1 | 5 | 17 |
| Postmenopause | D017698 | — | — | 5 | 1 | 2 | 1 | 1 | 10 |
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | 1 | 1 | — | 1 | 1 | 4 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | 1 | — | 2 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | 1 | — | 1 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | — | 1 | — | 1 |
| Psychotic affective disorders | D000341 | — | F39 | — | — | — | 1 | — | 1 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | — | — | 1 | — | 1 |
| Depression | D003863 | — | F33.9 | — | — | — | 1 | — | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Menopause | D008593 | EFO_0003922 | N95 | 4 | 2 | 1 | — | — | 7 |
| Endometrial hyperplasia | D004714 | — | N85.0 | — | — | 2 | — | — | 2 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | — | 1 | — | — | 1 |
| Apnea | D001049 | — | R06.81 | — | — | 1 | — | — | 1 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | — | 1 | — | — | 1 |
| Hyperplasia | D006965 | EFO_0000536 | — | — | — | 1 | — | — | 1 |
| Atrophy | D001284 | — | — | — | — | 1 | — | — | 1 |
| Atrophic vaginitis | D059268 | EFO_1001271 | — | — | — | 1 | — | — | 1 |
| Hot flashes | D019584 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 4 | — | — | 1 | 7 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 2 | — | — | — | 2 |
| Sclerosis | D012598 | — | — | — | 2 | — | — | — | 2 |
| Risk reduction behavior | D040242 | — | — | — | 1 | — | — | — | 1 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | 1 | — | — | — | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | 1 | — | — | — | 1 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 1 | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
| Carcinoma in situ | D002278 | — | D09.9 | — | 1 | — | — | — | 1 |
| Breast carcinoma in situ | D000071960 | — | D05 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 6 | — | — | — | — | 6 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 1 | — | — | — | — | 1 |
| Sleep | D012890 | GO_0030431 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | — | — | 1 | 1 |
| Adenocarcinoma | D000230 | — | — | — | — | — | — | 1 | 1 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | — | 1 | 1 |
| Mortality | D009026 | EFO_0004352 | — | — | — | — | — | 1 | 1 |
| Drug therapy | D004358 | — | — | — | — | — | — | 1 | 1 |
| Osteoporotic fractures | D058866 | — | — | — | — | — | — | 1 | 1 |
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bazedoxifene |
| INN | bazedoxifene |
| Description | Bazedoxifene is a phenylindole. |
| Classification | Small molecule |
| Drug class | antiestrogens of the clomifene and tamoxifen groups |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12 |
Identifiers
| PDB | — |
| CAS-ID | 198481-32-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL46740 |
| ChEBI ID | — |
| PubChem CID | 154257 |
| DrugBank | DB06401 |
| UNII ID | Q16TT9C5BK (ChemIDplus, GSRS) |
Target
Agency Approved
ESR2
ESR2
Organism
Homo sapiens
Gene name
ESR2
Gene synonyms
ESTRB, NR3A2
NCBI Gene ID
Protein name
estrogen receptor beta
Protein synonyms
estrogen receptor beta 2, estrogen receptor beta 4, Nuclear receptor subfamily 3 group A member 2, oestrogen receptor beta
Uniprot ID
Mouse ortholog
Esr2 (13983)
estrogen receptor beta (O08537)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,535 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,033 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use